x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:13:46

Menlo Ventures published a report showing that the...

BiotechTV - News ·

2025/11/05

Menlo Ventures Partner, and co-author of the report, Derek Xiao talks about how AI is improving the P&L of health systems and helping with staffing shortages. Medical documentation, billing and scribing are the biggest areas of adoption today, while patient engagement and the post acute relationship are emerging as next to be impacted.

en-us

00:07:53

BIO-Europe 2025: Spain based ARTHEx Biotech is a...

BiotechTV - News ·

2025/11/04

CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The company raised an $87M series B in September.

en-us

00:08:03

BIO-Europe 2025: Sparrow Pharmaceuticals raised a...

BiotechTV - News ·

2025/11/04

CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients.

en-us

00:08:02

BIO-Europe 2025: Topas Therapeutics is delivering...

BiotechTV - News ·

2025/11/04

CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week.

en-us

00:06:43

BIO-Europe 2025: Step Pharma has 'followed the...

BiotechTV - News ·

2025/11/04

He explains the story of this enzyme and the biology of how CTPS1 and CTPS2 interact. Step is in the clinic in lymphoma and solid tumors, and recently raised a €38 series C.

en-us

00:10:52

BIO-Europe 2025: Barcelona based Connecta...

BiotechTV - News ·

2025/11/04

CEO Jordi Fàbrega and CFO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.

en-us

00:09:53

BIO-Europe 2025: Switzerland based ReproNovo is...

BiotechTV - News ·

2025/11/03

CEO Jean Marie Duvall describes the company's programs, one focused on male inferitliy and another that may have dual purposes of helping with embryo implantation and adenomyosis. She says to make sure there is a clear commercial path if when you focus on this field.

en-us

00:11:11

BIO-Europe 2025: Anavo Therapeutics is focused on...

BiotechTV - News ·

2025/11/03

CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development.

en-us

00:10:12

BIO-Europe 2025: Herantis Pharma is developing...

BiotechTV - News ·

2025/11/03

CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year.

en-us

00:16:34

BIO-Europe 2025: Valneva's partner Pfizer has been...

BiotechTV - News ·

2025/11/03

Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine.

en-us

00:15:41

Roche will pay Manifold Bio $55M up front, and up to...

BiotechTV - News ·

2025/11/03

Manifold Co-Founders Gleb Kuznetsov and Pierce Ogden explain how Manifold is working on next generation shuttles, which means going beyond transferrin. They discuss the deal, and also Manifold's broader platform of high-throughput, in-vivo discovery work.

en-us

00:09:45

BIO-Europe 2025: ReNewVax CEO Neil Murray believes...

BiotechTV - News ·

2025/11/03

He describes the unmet need for a better vaccine than those already on the market, and says he is looking for a lead investor for a series A at BIO-Europe.

en-us

00:12:51

BIO-Europe 2025: Abivax CEO Marc de Garidel discusses...

BiotechTV - News ·

2025/11/03

He describes the mechanism of the therapy, as well the data and commercial landscape for UC. Plus, how he thinks about combos and business development.

en-us

00:10:41

BIO-Europe 2025: AAVantgarde Bio, which is working on...

BiotechTV - News ·

2025/11/03

CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of delivering genes that are naturally too large for single AAV vectors.

en-us

00:23:33

Mathai Mammen recaps the first clinical data...

BiotechTV - News ·

2025/10/31

He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.

en-us

00:13:00

BiotechTV visited South San Francisco based Noetik...

BiotechTV - News ·

2025/10/30

Co-Founder and CEO Ron Alfa walked BiotechTV's Ryan Flinn through how machine learning is taking cancer cell biology beyond the microscope.

en-us

00:23:18

Sonoma Biotherapeutics announced early clinical data...

BiotechTV - News ·

2025/10/30

They explain why they believe a Treg based cell therapy is the right approach for autoimmune conditions, and describe the construct of this particular product. After discussing the data, they also comment on what they believe the big picture is for these types of Treg based treatments going forward.

en-us

00:10:10

Zag Bio launched today with $80M, and aims to tackle...

BiotechTV - News ·

2025/10/28

CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.

en-us

00:11:21

Hemab Therapeutics, a company specializing in...

BiotechTV - News ·

2025/10/27

The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026. Hemab also has a monovalent antibody (HMB-022) in the clinic for the world's most common bleeding disorder, Von Willebrand Disease, and will be announcing an additional candidate next year.

en-us

00:08:41

Weave Bio, which raised a $20M series A this month,...

BiotechTV - News ·

2025/10/23

Co-Founder & CEO Brandon Rice says that in one project it worked on with a pharma, Weave's technology took only 3 hours to draft regulatory documents what would have taken humans to 100 hours.

en-us

342 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter